Company*
(Country; Symbol)

University/Nonprofit@

Type Of Agreement

Product Area

Details (Date)

CombiMatrix Group (unit of Acacia Research Corp.; CBMX)

U.S. Army Medical Institute of Infectious Diseases

Cooperative Research and Development Agreement

To use microarray approaches for detection of biothreat agents

They will work to design detection systems, develop assays for agents of interest, and evaluate system performance (11/18)

CombiMatrix Group (unit of Acacia Research Corp.; CBMX)

Harvard University

Research program

Use CombiMatrix arrays to map 3-D binding sites for oligonucleotides on folded RNA molecules

Gregory Verdine in Harvard's department of chemistry and chemical biology will work to discover discontinuous RNA epitopes as drug targets (11/10)

Amersham plc (UK; NYSE:AHM)

University of Pittsburgh

License

A class of molecules targeting amyloid plaque in the brain

Amersham plans to identify a lead candidate for clinical evaluation as a PET diagnostic for Alzheimer's disease (11/11)

Australian Cancer Technology (Australia; ASX:ACU)

Telethon Institute for Child Health Research (Australia)

Partnership

A test that can detect the loss of genes in cancer cells

Australian Cancer agreed to work with the institute to commercialize the technology developed at the institute (11/13)

Chembridge Research Laboratories LLC*

Memorial Sloan-Kettering Cancer Center

Collaboration

Chembridge will provide collections of small molecules to support discovery of cancer drugs

Sloan-Kettering will profile the biological activity of the libraries; terms of the five- year deal were not disclosed (11/11)

Chiron Vaccines (unit of Chiron Corp.; CHIR)

Health Protection Agency (UK)

License

Patent for the manufacture of a meningitis B vaccine

Chiron got an exclusive license; it will pay the HPA a sign-on fee as well as potential milestone and royalty payments (11/5**)

Diversa Corp. (DVSA)

San Diego Zoo

Collaboration

To collect samples of microbial communities from endangered species

The work is expected to benefit the zoo and help Diversa identify potential product candidates (11/10)

Elusys Therapeutics Inc.*

University of Pennsylvania

Development collaboration

To apply Heteropolymer technology from Elusys to thrombolytic technology from the university

The technology is for binding thrombolytics; Elusys has an option to license resulting technology after the two-year deal (11/10)

Enzon Pharmaceuticals Inc. (ENZN)

National Institutes of Health

Cooperative Research and Development Agreement

To develop the recombinant immunotoxin SS1P for pancreatic and ovarian carcinomas

Enzon will share development responsibilities and has applied to license worldwide rights to the Phase I fusion protein; the three-year CRADA also includes a project to further optimize SS1P (11/19)

GeneMax Corp. (OTC BB:GMXX)

National Institute of Allergy and Infectious Diseases

Nonexclusive worldwide license

For use of modified vaccinia ankara

GeneMax will use the technology to develop a vaccine platform capable of protecting against smallpox infection (11/17)

Gen-Probe Inc. (GPRO)

National Heart, Lung and Blood Institute

Contract extension

To develop a nucleic acid test for detecting West Nile virus in donated blood and organs

Gen-Probe gets $4.3M in supplemental funding from the 1999 contract; the award now totals about $15.5M and could reach $29.5M for work also including HIV and hepatitis B and C (11/12)

GenVec Inc. (GNVC)

National Institute of Allergy and Infectious Diseases

Subcontract technology

Manufacturing of vaccine candidates using GenVec's adenovector from $10M (11/5)

The expansion of the subcontract increases the potential funding over three years to $16M

Genzyme Corp. (GENZ)

National Kidney Foundation

Joint educational initiative

To develop print and online educational materials related to Fabry's disease

The goal is to raise awareness among patients and professionals (11/12)

Ingenuity Systems Inc.*

Stanford University

License

Stanford licensed the company's Pathways Analysis biology application

The parties also are collaborating to develop new functionality in the area of systems biology (11/3)

Large Scale Biology Corp. (LSBC)

Cincinnati Children's Hospital Medical Center

Exclusive license agreement

LSBC's license includes use of lysosomal acid lipase for atherosclerosis

LSBC gets rights to work described in a recent scientific publication; it plans to seek a development partner; terms were not disclosed (11/18)

Nanoscience Technologies Inc. (OTC BB:NANS)

New York University

License agreement

Nanoscience licensed technology in the area of DNA nanotechnology

Nanoscience is paying NYU about $1.66M through April 2007 for worldwide rights and the right to sublicense; it also gave shares to NYU and would pay royalties on sales or sublicenses (11/20)

Paratek Pharmaceuticals Inc.*

Families of Spinal Muscular Atrophy

Development partnership

Use of Paratek's small molecules as potential treatment for spinal muscular atrophy

Investigators supported by Families of SMA will test the compounds in the lab and in models of disease to evaluate their potential (11/17)

Peplin Biotech Ltd. (Australia; ASX:PEP)

Women & Children's Hospital (Australia)

License agreement

Peplin secured rights to 44 polyunsaturated fatty-acid compounds

Peplin is paying A$255,000 (US$0.16M) up front as well as 200,000 ordinary shares and options; Peplin also would pay milestones with stock (11/20)

Pintex Pharmaceuticals Inc.*

Max Plank Research Unit for Enzymology of Protein Folding (Germany)

Exclusive license agreement

Pintex acquired worldwide rights to technology related to the Pin1 enzyme

The license strengthens Pintex's position on the enzyme, which has been linked to cancers; it plans to begin preclinical development of a small-molecule inhibitor (11/18)

Third Wave Technologies Inc. (TWTI)

Mayo Medical Laboratories at Mayo Clinic

Supply agreement

Third Wave's Invader technology for genetic testing of blood-clotting and cardiovascular disease factors

Mayo will use the technology to test various mutations; terms were not disclosed (11/12)

Tm Bioscience Corp. (Canada; TSE:TMC)

Mayo Foundation

Master purchase agreement

Five-year deal under which Mayo will buy the Tag-It Mutation Detection Kit for CFTR (cystic fibrosis gene)

The deal represents an expansion of agreement to include the CFTR kit; terms were not disclosed (11/20)

Transgene SA (France; TRGNY)

French AIDS Research Agency and INSERM (France)

Manufacturing agreement

AIDS vaccine consisting of modified vaccinia ankara vectors carrying virus epitopes

Transgene will construct and manufacture preclinical lots and receive payment for the service (11/3)

SRI International*

National Cancer Institute

Contract

For synthesis of certain chemical carcinogens as chemoprotective agents

SRI got a three-year, $1.52M contract for the work (11/4)

Vical Inc. (VICL) being developed by an NIH unit

National Institutes of Health

Nonexclusive license agreement

Gene sequences used in a DNA vaccine against Ebola based on Vical's delivery technology

Vical acquired right to commercialize the vaccine if it gains FDA approval; human safety testing has begun (11/18)

Zyomyx Inc.*

National Eye Institute

Purchase agreement

The Zyomyx Protein Profiling Biochip System for research in ocular diseases

The institute selected the system for research use; terms were not disclosed (11/4)

Notes:

This chart does not include grant agreements (unless they are also part of a larger collaboration) or agreements between biotech companies and clinical trial centers.

* Denotes privately held company.

** Denotes date item ran in BioWorld International.

@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted.

Unless otherwise noted, shares are traded on the Nasdaq exchange.

ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.